Ranitidine

Ranitidine

SCHEMBL5928192

CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH2

The experimentally established mechanism targets of Ranitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 known ✓ P25021 1/20 0.98
RAD52 P43351 3/20 1.00
MAPT P10636 1/20 1.00
BLM P54132 1/20 1.00
ACHE P22303 15/20 0.98
MEN1 O00255 1/20 0.98
SLC22A1 O15245 1/20 0.98
ABCB11 O95342 1/20 0.98
LMNA P02545 1/20 0.98
CHRM2 P08172 1/20 0.98
CHRM1 P11229 1/20 0.98
TSHR P16473 1/20 0.98
ADRA2C P18825 1/20 0.98
NFKB1 P19838 1/20 0.98
CHRM3 P20309 1/20 0.98
ATP4A P20648 1/20 0.98
PTGS1 P23219 1/20 0.98
SLC6A4 P31645 1/20 0.98
CYP2C19 P33261 1/20 0.98
ADRA1A P35348 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ranitidine SCHEMBL8110889 1.00 RAD52 (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL33299 1.00 RAD52 (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL33298 1.00 RAD52 (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL8819146 1.00 RAD52 (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL2228178 0.99 RAD52 (0.98) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL824 0.99 ACHE (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL8594797 0.99 ACHE (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL8796367 0.99 ACHE (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL825 0.99 ACHE (1.00) RAD52MAPTBLMACHEMEN1
Ranitidine SCHEMBL826 0.99 ACHE (1.00) RAD52MAPTBLMACHEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855835-B2 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative PHARMEXCEL SRL (IT) 2005-02-15 US claimed
US-20040048922-A1 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative PHARMEXCEL SRL (IT) 2004-03-11 US claimed
WO-2020239685-A1 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING UVEAL MELANOMA UNIVERSITEIT GENT (BE) 2020-12-03 WO disclosed
US-8471011-B2 Preparation of acid addition salts of amine bases by solid phase—gas phase reactions APOTEX PHARMACHEM INC. (CA) 2013-06-25 US disclosed
US-20060205944-A1 Preparation of acid addition salts of amine bases by solid phase-gas phase reactions APOTEX PHARMACHEM INC. 2006-09-14 US disclosed
US-6855835-B2 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative PHARMEXCEL SRL (IT) 2005-02-15 US disclosed
US-6855835-B2 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative PHARMEXCEL SRL (IT) 2005-02-15 US disclosed
US-20040267030-A1 Novel process for the preparation of form 1 ranitidine hydrochloride AVENTIS PHARMACEUTICALS INC. 2004-12-30 US disclosed
US-20040048922-A1 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative PHARMEXCEL SRL (IT) 2004-03-11 US disclosed
US-20040048922-A1 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative PHARMEXCEL SRL (IT) 2004-03-11 US disclosed
EP-1265879-A1 ALLOMORPH ISOMER Z HYDROCHLORIDE OF RANITIDINE Pharmexcel SRL (IT) 2002-12-18 EP disclosed
US-20020151729-A1 Novel process for the preparation of form 1 ranitidine hydrochloride CHENG WEN J (US) 2002-10-17 US disclosed
WO-2001064662-A1 ALLOMORPH ISOMER Z HYDROCHLORIDE OF RANITIDINE PHARMEXCEL SRL (IT) 2001-09-07 WO disclosed
US-4968808-A MULTISTEP IN ONE POT HEUMANN PHARMA GMBH & CO. (DE) 1990-11-06 US disclosed
EP-0219225-B1 PROCESS FOR THE PREPARATION OF RANITIDINE OR ACID ADDITION SALTS THEREOF, AND INTERMEDIATES FOR THIS PREPARATION A/S GEA Farmaceutisk Fabrik (DK) 1989-02-22 EP disclosed
US-4279819-A GASTROINTESTINAL DISORDERS ALLEN & HANBURYS LTD. (GB) 1981-07-21 US disclosed
US-4255440-A ANTIALLERGENS, ANTIULCER AGENTS ALLEN & HANBURYS LIMITED (GB) 1981-03-10 US disclosed
US-4169855-A ANTIHISTAMINES, ANTISECRETORY AGENTS Allen & Hansbury, Limited (GB) 1979-10-02 US disclosed
US-4128658-A HISTAMINE ANTAGONISTS ALLEN & HANBURYS LIMITED (GB) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205944-A1 Preparation of acid addition salts of amine bases by solid phase-gas phase reactions POLR2A, AVPR1B, AVPR2 HRH2 12/4885RAD52 4397/4885MAPT 314/4885
US-20040048922-A1 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative SHBG, NR5A1, OPRM1 HRH2 3536/4885RAD52 2696/4885MAPT 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.